ORIC Pharmaceuticals Inc
ORIC
Company Profile
Business description
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Contact
240 E. Grand Avenue
2nd Floor
South San FranciscoCA94080
USAT: +1 650 388-5600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
128
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
Siteminder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
stocks
Impact of ANZ’s huge fine
Working to prevent repeated failures could also improve competitiveness.
stocks
Acquisition a sign of weakness for overvalued ASX share
Acquisition unlikely to improve prospects in the US and detracts from other opportunities.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,091.80 | 30.70 | -0.34% |
| CAC 40 | 7,818.22 | 78.71 | -1.00% |
| DAX 40 | 23,329.24 | 419.62 | -1.77% |
| Dow JONES (US) | 45,757.90 | 125.55 | -0.27% |
| FTSE 100 | 9,195.66 | 81.37 | -0.88% |
| HKSE | 26,812.19 | 373.68 | 1.41% |
| NASDAQ | 22,333.96 | 14.79 | -0.07% |
| Nikkei 225 | 44,915.67 | 13.40 | 0.03% |
| NZX 50 Index | 13,193.02 | 41.87 | -0.32% |
| S&P 500 | 6,606.76 | 8.52 | -0.13% |
| S&P/ASX 200 | 8,816.60 | 31.90 | -0.36% |
| SSE Composite Index | 3,877.55 | 15.68 | 0.41% |